#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Deafness neurosensory Fontan procedure Glioblastoma multiforme Round cell liposarcoma Neuroendocrine cell hyperplasia of infancy Mantle cell lymphoma stage IV Hepatitis B Fatty acid oxidation disorder Angiosarcoma non-metastatic VEXAS syndrome Juvenile idiopathic arthritis Neoplasm malignant Osteomyelitis Retinitis pigmentosa Short-bowel syndrome More trials…

    Learn about Rare Diseases

    Lymphangioma – Diagnostics Rosai-Dorfman syndrome – Trials in Disease Gaucher’s disease type I – Basic Information Congenital hypotransferrinaemia – Trials in Disease Cytokine release syndrome Ewing’s sarcoma metastatic – Treatment Congenital generalised lipodystrophy Acute respiratory distress syndrome – Life with Disease Bronchiolitis obliterans syndrome Systemic sclerosis pulmonary – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hydralazine Hydrochloride Vindesine Sulfate Exidavnemab Amg 193 Iloprost Trometamol Reparixin Gs-4182 Neostigmine Methylsulfate Gedatolisib Resmetirom Tildacerfont Quizartinib Dihydrochloride D5-Ethyl-Beta-D-Glucuronide Lithium Sulphate, Anhydrous XYLOMETAZOLINE HYDROCHLORIDE Epacadostat Voxelotor Bi 764524 Etoricoxib Methoxsalen More therapies…

    Learn about Your Condition

    Epilepsy H1N1 influenza Pemphigoid Myxofibrosarcoma Tetanus Metabolic syndrome Habitual abortion Ewing's sarcoma recurrent Biliary cancer metastatic Anal cancer stage II Gastrointestinal melanoma Hidradenitis Embolism Metastases to biliary tract Febrile neutropenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Denmark France Portugal Spain

  • Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Golcadomide
    • Bendamustine Hydrochloride
    • Betamethasone Sodium Phosphate
    Finland France Germany Greece Italy The Netherlands +2

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4

  • Study on Adding Darolutamide to First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    • Cabazitaxel
    • Lutetium (177Lu) Oxodotreotide
    Spain

  • Study on Long-term Safety and Efficacy of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic inflammatory demyelinating polyradiculoneuropathy
    Investigated Drugs:
    • Riliprubart
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines

    Recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Belgium Bulgaria Croatia Czechia Estonia Germany +6

  • Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Mrna-4157
    Denmark France Germany Greece Hungary Italy +3

  • Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Degarelix
    • Leuprorelin Acetate
    • Relugolix
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study on the Effects of Pitolisant Hydrochloride for Patients with Prader-Willi Syndrome

    Recruiting

    3 1
    Investigated Diseases:
    • Prader-Willi syndrome
    Belgium Czechia Denmark France Germany Italy +4
Previous Page
1 2 3 4 5 6 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!